

Comment on [Wimberger et al](#), page 1985

# What's brewing for MALT1 in lymphoma?

Marcel Spaargaren | Amsterdam UMC - University of Amsterdam

**The paracaspase mucosa-associated lymphoid tissue 1 (MALT1) is a protease and scaffold protein, essential in propagating signals from the B-cell receptor (BCR) and various oncogenic proteins to NF- $\kappa$ B; hence, it is a potential therapeutic target for treatment of a variety of B-cell malignancies. In this issue of *Blood*, [Wimberger et al](#) study the protease function of MALT1 in chronic BCR signaling and signaling by oncogenic CARD11 in activated B cell-like diffuse large B-cell lymphoma (ABC-DLBCL) and of the API2-MALT1 fusion oncoprotein in MALT lymphoma.<sup>1</sup>**

Most mature B-cell malignancies depend on (chronic) BCR- and/or oncogenic protein-propagated constitutive canonical NF- $\kappa$ B signaling for their growth and survival. This is illustrated by recurrent gain-of-function mutations in *CD79*, *CARD11*, *BCL10*, and *MYD88* and loss-of-function deletions/mutations in *TNFAIP3* (A20) in DLBCL; the chromosomal translocation product API2-MALT1 in MALT lymphoma; and the clinical efficacy of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib in chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), marginal zone lymphoma, and DLBCL.

Formation of a complex composed of the caspase recruitment domain family member 11 (*CARD11*), B-cell lymphoma 10 (*BCL10*), and MALT1, the CBM complex, is a key intermediate in signaling of the BCR to canonical NF- $\kappa$ B activation.<sup>2</sup> MALT1 functions as a scaffold protein, allowing recruitment and activation of the E3-ubiquitin ligase tumor necrosis factor receptor-associated factor 6 (*TRAF6*). *TRAF6* mediates Lys-63-linked polyubiquitination of the regulatory  $\gamma$  subunit of the I $\kappa$ B kinase (IKK) complex (IKK- $\gamma$  or NEMO), thereby contributing to its activation, which results in phosphorylation and proteasomal degradation of I $\kappa$ B and dissociation and nuclear translocation of NF- $\kappa$ B (see [figure](#)).<sup>2,3</sup> Next to its function as a scaffold protein, MALT1 possesses protease activity and is able to cleave and inactivate negative regulators of canonical NF- $\kappa$ B signaling, such as

A20, RelB, and CYLD (see [figure](#)).<sup>1-3</sup> Recently, it was demonstrated that low expression of the deubiquitinating enzyme CYLD, which can hydrolyze Lys-63-linked ubiquitin chains of *TRAF6* and IKK- $\gamma$ , is associated with a poor prognosis of patients with ABC-DLBCL and MCL and that chronic BCR signaling propagates MALT1-mediated cleavage and proteasomal degradation of CYLD, thereby contributing to canonical NF- $\kappa$ B signaling and growth of BCR-dependent lymphomas.<sup>3</sup>

Underlining the critical role of MALT1 in propagating NF- $\kappa$ B activity, inhibition of MALT1 proteolytic activity impairs growth and survival of MCL and ABC-DLBCL in the preclinical setting, and various MALT1 inhibitors are currently under clinical investigation for mature B-cell malignancies (outlined below).<sup>2,3</sup> However, despite these recent preclinical and clinical developments, as of yet the role of the MALT1 protease activity in lymphomagenesis remains incompletely understood.


In the current study, [Wimberger et al](#) combined CRISPR/Cas9-mediated knockout of MALT1 or *TRAF6*, ectopic expression of function-compromised MALT1 mutants, and pharmacological MALT1 inhibition to study canonical NF- $\kappa$ B signaling evoked by PMA/ionomycin stimulation (to mimic BCR signaling) and oncogenic *CARD11*. They demonstrate that most target genes are codependent on MALT1 protease activity and *TRAF6*

binding, reflecting the scaffold function of MALT1, for optimal expression. However, some genes are only MALT1 protease dependent. These included *NFKBIZ* (I $\kappa$ B $\zeta$ ), *NFKBID* (I $\kappa$ BNS), and *ZC3H12A* (regnase-1) (see [figure](#)), which are also highly expressed in ABC-DLBCL. Interestingly, of these genes, only *NFKBIZ* is under transcriptional control of NF- $\kappa$ B,<sup>1,4</sup> indicating that the MALT1 protease exerts effects beyond NF- $\kappa$ B to control expression of I $\kappa$ BNS and regnase-1.

At the protein level, the RNA-binding protein (RBP) regnase-1 and other RBPs named roquin-1 and -2 were found to be constitutively cleaved and inactivated by MALT1,<sup>5,6</sup> which was also observed in ABC-DLBCL cells (see [figure](#)). The cleavage of these RBPs, and the expression of the MALT1 protease-dependent genes, is repressed by treatment with the BTK inhibitor ibrutinib and MALT1 protease inhibitors. Furthermore, in ABC-DLBCL cells, the stability of the *NFKBIZ* and *NFKBID* transcripts is repressed by binding of the RBPs to their 3'UTRs, which is promoted by ibrutinib and MALT1 inhibitor treatment. This repression by the RBPs is abolished by previously identified<sup>7</sup> recurrent mutations in the RBP binding sequence in the 3'UTR of *NFKBIZ* in ABC-DLBCL (see [figure](#)). Finally, similar results are presented for the protease activity of the API2-MALT1 oncoprotein, at the transcriptional, posttranscriptional, and posttranslational levels.

Taken together, these novel findings indicate that MALT1 protease activity controls gene expression not only at the transcriptional but also at the post-transcriptional level by cleaving RBPs, resulting in enhanced expression of NF- $\kappa$ B-dependent and -independent genes in ABC-DLBCL and MALT lymphoma.

This study provides novel insights into the molecular mechanisms underlying MALT1-mediated NF- $\kappa$ B signaling and how direct inhibition of MALT1 protease activity, but also indirect inhibition of MALT1 by other BCR signalosome inhibitors such as ibrutinib, may contribute to the antilymphoma effects of these drugs. These findings have clinical relevance for the development of therapeutic strategies aimed at targeting MALT1 or downstream effectors as treatment for (mature) B-cell



Simplified model of the role of MALT1 and regnase-1 in B-cell lymphoma. BCR signaling through BTK mediates the formation of a complex of CARD11, BCL10, and MALT1. Oligomerized MALT1, but also the oncoprotein API2-MALT1, functions as a scaffold protein, binding the E3 ubiquitin ligase TRAF6. In parallel, Toll-like receptor (TLR) signaling may result in MyD88-dependent recruitment of IRAK4 and IRAK1, which can also associate with TRAF6. TRAF6 promotes Lys-63-linked ubiquitination of TRAF6 itself as well as TAK1 and IKK- $\gamma$ /NEMO, resulting in their interaction and TAK1-mediated activation of IKK. IKK mediates phosphorylation and degradation of  $\text{I}\kappa\text{B}\alpha$ , allowing nuclear translocation of NF- $\kappa\text{B}$  dimers. In addition, MALT1 (and API2-MALT1) is a protease that cleaves various negative regulators of NF- $\kappa\text{B}$ , such as A20, CYLD, and RelB. The deubiquitinating enzymes A20 and CYLD hydrolyze Lys-63-linked polyubiquitin chains of TRAF6, TAK1, and/or NEMO/IKK- $\gamma$ , whereas RelB can interact with and repress activity of canonical NF- $\kappa\text{B}$  subunits; hence, MALT1-dependent inactivation of A20, CYLD, and RelB promotes NF- $\kappa\text{B}$  activation and cell growth. The study by Wimberger et al shows that MALT1 protease activity can also regulate gene expression independent of TRAF6/NF- $\kappa\text{B}$ , at the posttranscriptional level, by inactivation of the RNA-binding proteins regnase-1 and roquin-1/2, thereby promoting the stability of the *NFKBIZ* ( $\text{I}\kappa\text{B}\zeta$ ), *NFKBID* ( $\text{I}\kappa\text{BNS}$ ), and *ZC3H12A* (regnase-1) transcripts. Similar findings are presented for the API2-MALT1 oncoprotein. Professional illustration by Somersault18:24.

malignancies. Furthermore, the identified MALT1 protease-specific target genes may serve as suitable biomarkers for clinical studies.

Despite promising preclinical results, the MALT1 inhibitory peptide z-VRPR-fmk and the irreversibly binding pharmacological inhibitor MI-2 turned out to be unsuitable for clinical use, whereas the reversible MALT1 inhibitory phenothiazine derivatives and the pyrazolopyrimidine derivatives (MLT-XXX) have not yet been studied clinically. However, for several other MALT1 (protease) inhibitors, ie,

safimaltib (JNJ-67856633) (ClinicalTrials.gov: NCT03900598 and NCT04876092), ONO-7018 (CTX-177) (NCT05515406), SGR-1505 (NCT05544019), and ABBV-525 (NCT05618028), clinical trials are currently active for various (mature) B-cell malignancies. Of note, MALT1 inhibitors also have clinical potential for patients with primary resistance to ibrutinib, eg, patients with DLBCL with CARD11 or BCL10 mutations, or patients who developed secondary ibrutinib resistance, eg, patients with MCL or CLL with acquired mutations of the ibrutinib-binding cysteine residue in BTK.<sup>8,9</sup>

The novel insights provided by Wimberger et al and other recent studies,<sup>3,8-10</sup> as well as future studies on the specific roles of the distinct protease and scaffold functions of MALT1, may pave the way toward precision treatment by informed combinations of small-molecule inhibitors or PROTAC degraders of specific kinases, ubiquitinating enzymes, or transcription factors downstream of MALT1, targeting, for example, TRAF6, IKK, or individual NF- $\kappa\text{B}$  subunits. Such an informed precision approach to selectively suppress (a combination of) distinct canonical or noncanonical NF- $\kappa\text{B}$  signals would provide a promising therapeutic strategy for mature B-cell malignancies.

*Conflict-of-interest disclosure:* The author declares no competing financial interests. ■

## REFERENCES

- Wimberger N, Ober F, Avar G, et al. Oncogene-induced MALT1 protease activity drives posttranscriptional gene expression in malignant lymphomas. *Blood*. 2023;142(23):1985-2001.
- O'Neill TJ, Tofaute MJ, Krappmann D. Function and targeting of MALT1 paracaspase in cancer. *Cancer Treat Rev*. 2023;117:102568.
- Minderman M, Lantermans HC, Grüneberg LJ, et al. MALT1-dependent cleavage of CYLD promotes NF- $\kappa\text{B}$  signaling and growth of aggressive B-cell receptor-dependent lymphomas. *Blood Cancer J*. 2023;13(1):37.
- Nogai H, Wenzel SS, Hailfinger S, et al.  $\text{I}\kappa\text{B}\alpha$ -zeta controls the constitutive NF- $\kappa\text{B}$  target gene network and survival of ABC DLBCL. *Blood*. 2013;122(13):2242-2250.
- Jeltsch KM, Hu D, Brenner S, et al. Cleavage of roquin and regnase-1 by the paracaspase MALT1 releases their cooperatively repressed targets to promote T(H)17 differentiation. *Nat Immunol*. 2014;15(11):1079-1089.
- Uehata T, Iwasaki H, Vandenbon A, et al. Malt1-induced cleavage of regnase-1 in CD4(+) helper T cells regulates immune activation. *Cell*. 2013;153(5):1036-1049.
- Arthur SE, Jiang A, Grande BM, et al. Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma. *Nat Commun*. 2018;9(1):4001.
- Xia M, David L, Teater M, et al. BCL10 mutations define distinct dependencies guiding precision therapy for DLBCL. *Cancer Discov*. 2022;12(8):1922-1941.
- Jiang VC, Liu Y, Lian J, et al. Cotargeting of BTK and MALT1 overcomes resistance to BTK

## MYELOID NEOPLASIA

Comment on [Man et al](#), page 2002

# PLK4, a potential target against AML

Caroline Palm-Apergi | Karolinska Institutet

**In this issue of *Blood*, [Man et al](#) investigate the therapeutic potential of Polo-like kinase 4 (PLK4) in *TP53* mutated and wild-type acute myeloid leukemia (AML) cell lines, patient samples, and mouse models.<sup>1</sup> PLK4 is a member of the PLK family of 5 serine-threonine kinases involved in cell cycle regulation;<sup>2</sup> the family includes the more famous PLK1 that has been investigated in several clinical trials in AML and in other cancer diagnoses. The PLK1 inhibitor volasertib progressed up to a phase 3 study, where it was given as a combination treatment with cytarabine in patients with refractory AML.<sup>3</sup> Unfortunately, the addition of volasertib did not improve the overall survival but did result in worse adverse effects compared with the single-arm treatment with cytarabine. Although the clinical trial did not conclude if the adverse reactions were due to on- or off-target effects, several off-target proteins to volasertib have been identified that could explain some of the adverse effects;<sup>4</sup> thus, the 3-dimensional molecular structure is an important factor to take into consideration as it could result in off-target binding. Importantly, there are still ongoing clinical trials of volasertib and other PLK1 inhibitors as well as PLK4 inhibitors.**

The PLK family has a C-terminal polo-box domain that is representative of the family and an N-terminal kinase domain that contains the adenosine triphosphate (ATP) pocket, where ATP-competitive small molecules can bind and inactivate PLKs. Because the kinase domains of PLK1, PLK2, and PLK3 are structurally similar, selectivity may be an issue for PLK1 inhibitors. As PLK2 and PLK3 are believed to have tumor suppressor effects, PLK1 inhibitors may induce unwanted effects by targeting PLK2 and PLK3. PLK4, on the other hand, has a structurally different kinase domain, and small inhibitory molecules targeting PLK4 may be more selective, at least within the PLK family. Thus, PLK4 may have an advantage over PLK1.

In the current study, [Man et al](#) investigate both PLK4 inhibition by small inhibitory molecules, such as CFI-400945,<sup>5</sup> and knockdown of PLK4 by short hairpin RNA and find that both inhibition and

knockdown result in reduced proliferation by different mechanisms, depending on the *TP53* status of the AML cells. As CFI-400945 has been shown to inhibit Aurora B (another serine-threonine kinase with a key role in the cell cycle) as well,<sup>6</sup> the knockdown by RNA interference corroborates the suggestion that the effects are due to PLK4 and not Aurora B inhibition. Moreover, the PLK4 expression was found to be higher in AML cell lines and patient samples with mutated *TP53* compared to AML cells with wild-type *TP53*. In accordance with previous studies,<sup>7,8</sup> PLK4 expression was also significantly higher in samples of patients with AML compared with bone marrow from healthy donors, which is of importance for future clinical trials.

By comparing *TP53* wild-type and mutated AML cell lines, patient samples, and mouse models, including patient-derived xenografts, the authors show that inhibition of PLK4 in *TP53* mutated

AML cells remodels histone methylation and activates the immune response via the cyclic GMP-AMP synthase-stimulator of interferon genes pathway. More important, in both mutated and wild-type *TP53* AML cells, inhibition of PLK4 involves a novel PLK4/protein arginine methyltransferase 5/enhancer of zeste homolog 2/trimethylation of histone H3 at lysine 27 axis that could be the driver of the antileukemic effect that results in DNA damage, apoptosis, and reduced proliferation.

In *TP53* wild-type cells, PLK4 inhibition significantly suppresses cell growth during initial exposure, resulting in more apoptotic cells compared with the mutant *TP53* cells. However, DNA damage is induced in both *p53* wild-type and mutated AML cells, whereas senescence is only detected in *TP53* mutated AML cells. Prolonged inhibition of PLK4 by both small-molecule inhibitors and RNA interference reduced cell growth of mutated AML samples. More important, the small molecule CFI-400945 displayed cytotoxicity in *TP53* mutated AML cells but not in normal cells.

Using a *TP53* mutant AML mouse model, the authors show that PLK4 inhibition by small-molecule inhibitor CFI-400945 is more effective than a combination of cytarabine and doxorubicin (see Figure 5B in the article by [Man et al](#)). Similarly, PLK4 inhibition results in suppressed leukemic burden in *TP53* wild-type AML mice and in patient-derived xenografts (Figure 5D in the article), where mice have been engrafted with primary *TP53* mutated AML cells. Last, the combination of PLK4 inhibitor, CFI-400945, with an anti-CD47 antibody that inhibits the “don’t-eat-me” signal in macrophages, revealed a synergistic effect. The blockade of this signal could enhance macrophage-mediated phagocytosis, as suggested by the prolonged survival compared with single treatment (see Figure 5H in the article by [Man et al](#)). This reasoning was used in a phase 1b clinical trial in *TP53* mutated AML, where the combination of an anti-CD47 monoclonal antibody, magroglab, with azacitidine was investigated.<sup>9</sup>

PLK4 inhibition by CFI-400945 was previously studied in a phase 1 trial in advanced solid tumors,<sup>10</sup> and there are currently 2 clinical trials with the PLK4